Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
49.52
-1.99 (-3.86%)
Dec 3, 2024, 2:09 PM EST - Market open
Viking Therapeutics Employees
Viking Therapeutics had 27 employees as of December 31, 2023. The number of employees increased by 6 or 28.57% compared to the previous year.
Employees
27
Change (1Y)
6
Growth (1Y)
28.57%
Revenue / Employee
n/a
Profits / Employee
-$3,672,259
Market Cap
5.52B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 27 | 6 | 28.57% |
Dec 31, 2022 | 21 | 3 | 16.67% |
Dec 31, 2021 | 18 | -2 | -10.00% |
Dec 31, 2020 | 20 | 3 | 17.65% |
Dec 31, 2019 | 17 | -1 | -5.56% |
Dec 31, 2018 | 18 | 4 | 28.57% |
Dec 31, 2017 | 14 | 2 | 16.67% |
Dec 31, 2016 | 12 | 2 | 20.00% |
Dec 31, 2015 | 10 | 6 | 150.00% |
Jun 15, 2014 | 4 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Grifols | 23,737 |
RadNet | 8,441 |
Merit Medical Systems | 6,950 |
Stevanato Group | 5,634 |
Inspire Medical Systems | 1,011 |
Ionis Pharmaceuticals | 927 |
Blueprint Medicines | 655 |
Cytokinetics | 423 |
VKTX News
- 4 days ago - Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum - Benzinga
- 7 days ago - Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs - Benzinga
- 13 days ago - Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs - Benzinga
- 13 days ago - Viking Therapeutics is more than just a weight-loss stock, and that's drawing cheers - Market Watch
- 13 days ago - Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 - PRNewsWire
- 18 days ago - RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking. - Market Watch
- 20 days ago - Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 - PRNewsWire
- 25 days ago - Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca - CNBC